Oxysterols: From cholesterol metabolites to key mediators

Progress in Lipid Research

Volumn 64, Issue , 2016, Pages 152-169

  Mutemberezi, Valentin ^a   Guillemot Legris, Owein ^a   Muccioli, Giulio G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Bioactive lipids; Cytochrome; Hydroxycholesterol; INSIG; Oxysterome; Squalene epoxidase

Indexed keywords

22 HYDROXYCHOLESTEROL; 24 HYDROXYCHOLESTEROL; 24,25 EPOXYCHOLESTEROL; 24,27 DIHYDROXYCHOLESTEROL; 25 HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; 4BETA HYDROXYCHOLESTEROL; 5ALPHA,6ALPHA EPOXYCHOLESTEROL; 5ALPHA,6BETA DIHYDROXYCHOLESTEROL; 5BETA,6BETA EPOXYCHOLESTEROL; 6ALPHA HYDROXYCHOLESTEROL; 7 DEHYDROCHOLESTEROL; 7 KETO 25 HYDROXYCHOLESTEROL; 7 KETO 27 HYDROXYCHOLESTEROL; 7 OXOCHOLESTEROL; 7ALPHA HYDROXYCHOLESTENONE; 7ALPHA HYDROXYCHOLESTEROL; 7ALPHA,24 DIHYDROXYCHOLESTEROL; 7ALPHA,25 DIHYDROXYCHOLESTEROL; 7ALPHA,27 DIHYDROXYCHOLESTEROL; 7BETA HYDROXYCHOLESTEROL; 7BETA,27 DIHYDROXYCHOLESTEROL; CELL NUCLEUS RECEPTOR; CHOLESTENOIC ACID; DESMOSTEROL; HYDROLASE; OXIDOREDUCTASE; OXYSTEROL; TRANSFERASE; UNCLASSIFIED DRUG; CELL RECEPTOR; CHOLESTEROL; G PROTEIN COUPLED RECEPTOR;

ALLOSTERISM; BRAIN METABOLISM; CEREBROSPINAL FLUID LEVEL; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HUMAN; LIPID BLOOD LEVEL; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; STEROL ANALYSIS; STEROL METABOLISM; ANIMAL; ANIMAL MODEL; CHEMISTRY; METABOLISM;

ANIMALS; CHOLESTEROL; HUMANS; HYDROLASES; MODELS, ANIMAL; OXIDOREDUCTASES; OXYSTEROLS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; TRANSFERASES;

EID: 84991707546     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2016.09.002     Document Type: Review

References (216)

1. [1] Crick, P.J., Beckers, L., Baes, M., Van Veldhoven, P.P., Wang, Y., Griffiths, W.J., The oxysterol and cholestenoic acid profile of mouse cerebrospinal fluid. Steroids 99 (2015), 172–177.
2. [2] Griffiths, W.J., Abdel-Khalik, J., Hearn, T., Yutuc, E., Morgan, A.H., Wang, Y., Current trends in oxysterol research. Biochem. Soc. Trans. 44 (2016), 652–658.
3. [3] Luu-The, V., Assessment of steroidogenesis and steroidogenic enzyme functions. J. Steroid Biochem. Mol. Biol. 137 (2013), 176–182.
4. [4] Iuliano, L., Pathways of cholesterol oxidation via non-enzymatic mechanisms. Chem. Phys. Lipids 164 (2011), 457–468.
5. [5] Yin, H., Xu, L., Porter, N.A., Free radical lipid peroxidation: mechanisms and analysis. Chem. Rev. 111 (2011), 5944–5972.
6. [6] Diczfalusy, U., On the formation and possible biological role of 25-hydroxycholesterol. Biochimie 95 (2013), 455–460.
7. [7] Hashimoto, M., Kobayashi, K., Watanabe, M., Kazuki, Y., Takehara, S., Inaba, A., Nitta, S., Senda, N., Oshimura, M., Chiba, K., Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver. J. Lipid Res. 54 (2013), 2060–2068.
8. [8] Kato, K., Ohbuchi, M., Hamamura, S., Ohshita, H., Kazuki, Y., Oshimura, M., Sato, K., Nakada, N., Kawamura, A., Usui, T., Kamimura, H., Tateno, C., Development of murine Cyp3a knockout chimeric mice with humanized liver. Drug Metab. Dispos. 43 (2015), 1208–1217.
9. [9] Nakada, N., Kawamura, A., Kamimura, H., Sato, K., Kazuki, Y., Kakuni, M., Ohbuchi, M., Kato, K., Tateno, C., Oshimura, M., Usui, T., Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans. Biopharm. Drug Dispos. 37 (2016), 3–14.
10. [10] Ho, H., Pinto, A., Hall, S.D., Flockhart, D.A., Li, L., Skaar, T.C., Cadman, P., O'Connor, D.T., Wagner, U., Fineberg, N.S., Weinberger, M.H., Association between the CYP3A5 genotype and blood pressure. Hypertension 45 (2005), 294–298.
11. [11] Schwarz, M., Lund, E.G., Setchell, K.D., Kayden, H.J., Zerwekh, J.E., Bjorkhem, I., Herz, J., Russell, D.W., Disruption of cholesterol 7alpha-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. J. Biol. Chem. 271 (1996), 18024–18031.
12. [12] Schwarz, M., Russell, D.W., Dietschy, J.M., Turley, S.D., Alternate pathways of bile acid synthesis in the cholesterol 7alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding. J. Lipid Res. 42 (2001), 1594–1603.
13. [13] Jones, R.D., Lopez, A.M., Tong, E.Y., Posey, K.S., Chuang, J.C., Repa, J.J., Turley, S.D., Impact of physiological levels of chenodeoxycholic acid supplementation on intestinal and hepatic bile acid and cholesterol metabolism in Cyp7a1-deficient mice. Steroids 93 (2015), 87–95.
14. [14] Pandak, W.M., Schwarz, C., Hylemon, P.B., Mallonee, D., Valerie, K., Heuman, D.M., Fisher, R.A., Redford, K., Vlahcevic, Z.R., Effects of CYP7A1 overexpression on cholesterol and bile acid homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 281 (2001), G878–G889.
15. [15] Pullinger, C.R., Eng, C., Salen, G., Shefer, S., Batta, A.K., Erickson, S.K., Verhagen, A., Rivera, C.R., Mulvihill, S.J., Malloy, M.J., Kane, J.P., Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110 (2002), 109–117.
16. [16] van Mil, S.W., Houwen, R.H., Klomp, L.W., Genetics of familial intrahepatic cholestasis syndromes. J. Med. Genet. 42 (2005), 449–463.
17. [17] Schwarz, M., Lund, E.G., Lathe, R., Bjorkhem, I., Russell, D.W., Identification and characterization of a mouse oxysterol 7alpha-hydroxylase cDNA. J. Biol. Chem. 272 (1997), 23995–24001.
18. [18] Li-Hawkins, J., Lund, E.G., Turley, S.D., Russell, D.W., Disruption of the oxysterol 7alpha-hydroxylase gene in mice. J. Biol. Chem. 275 (2000), 16536–16542.
19. [19] Omoto, Y., Lathe, R., Warner, M., Gustafsson, J.A., Early onset of puberty and early ovarian failure in CYP7B1 knockout mice. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 2814–2819.
20. [20] Setchell, K.D., Schwarz, M., O'Connell, N.C., Lund, E.G., Davis, D.L., Lathe, R., Thompson, H.R., Weslie, T.R., Sokol, R.J., Russell, D.W., Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J. Clin. Invest. 102 (1998), 1690–1703.
21. [21] Tsaousidou, M.K., Ouahchi, K., Warner, T.T., Yang, Y., Simpson, M.A., Laing, N.G., Wilkinson, P.A., Madrid, R.E., Patel, H., Hentati, F., Patton, M.A., Hentati, A., Lamont, P.J., Siddique, T., Crosby, A.H., Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am. J. Hum. Genet. 82 (2008), 510–515.
22. [22] Roos, P., Svenstrup, K., Danielsen, E.R., Thomsen, C., Nielsen, J.E., CYP7B1: novel mutations and magnetic resonance spectroscopy abnormalities in hereditary spastic paraplegia type 5A. Acta Neurol. Scand. 129 (2014), 330–334.
23. [23] Tuckey, R.C., Cameron, K.J., Human placental cholesterol side-chain cleavage: enzymatic synthesis of (22R)-20 alpha,22-dihydroxycholesterol. Steroids 58 (1993), 230–233.
24. [24] Hu, M.C., Hsu, N.C., El Hadj, N.B., Pai, C.I., Chu, H.P., Wang, C.K., Chung, B.C., Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1. Mol. Endocrinol. 16 (2002), 1943–1950.
25. [25] Kim, C.J., Lin, L., Huang, N., Quigley, C.A., AvRuskin, T.W., Achermann, J.C., Miller, W.L., Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J. Clin. Endocrinol. Metab. 93 (2008), 696–702.
26. [26] Andersson, S., Davis, D.L., Dahlback, H., Jornvall, H., Russell, D.W., Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem. 264 (1989), 8222–8229.
27. [27] Cali, J.J., Russell, D.W., Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J. Biol. Chem. 266 (1991), 7774–7778.
28. [28] Lund, E., Bjorkhem, I., Furster, C., Wikvall, K., 24-, 25- and 27-hydroxylation of cholesterol by a purified preparation of 27-hydroxylase from pig liver. Biochim. Biophys. Acta 1166 (1993), 177–182.
29. [29] Rosen, H., Reshef, A., Maeda, N., Lippoldt, A., Shpizen, S., Triger, L., Eggertsen, G., Bjorkhem, I., Leitersdorf, E., Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J. Biol. Chem. 273 (1998), 14805–14812.
30. [30] Ali, Z., Heverin, M., Olin, M., Acimovic, J., Lovgren-Sandblom, A., Shafaati, M., Bavner, A., Meiner, V., Leitersdorf, E., Bjorkhem, I., On the regulatory role of side-chain hydroxylated oxysterols in the brain. Lessons from CYP27A1 transgenic and Cyp27a1(−/−) mice. J. J. Lipid Res. 54 (2013), 1033–1043.
31. [31] Repa, J.J., Lund, E.G., Horton, J.D., Leitersdorf, E., Russell, D.W., Dietschy, J.M., Turley, S.D., Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J. Biol. Chem. 275 (2000), 39685–39692.
32. [32] Saadane, A., Mast, N., Charvet, C.D., Omarova, S., Zheng, W., Huang, S.S., Kern, T.S., Peachey, N.S., Pikuleva, I.A., Retinal and nonocular abnormalities in Cyp27a1(−/−)Cyp46a1(−/−) mice with dysfunctional metabolism of cholesterol. Am. J. Pathol. 184 (2014), 2403–2419.
33. [33] Chen, W., Chen, G., Head, D.L., Mangelsdorf, D.J., Russell, D.W., Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 5 (2007), 73–79.
34. [34] Meir, K., Kitsberg, D., Alkalay, I., Szafer, F., Rosen, H., Shpitzen, S., Avi, L.B., Staels, B., Fievet, C., Meiner, V., Bjorkhem, I., Leitersdorf, E., Human sterol 27-hydroxylase (CYP27) overexpressor transgenic mouse model. Evidence against 27-hydroxycholesterol as a critical regulator of cholesterol homeostasis. J. Biol. Chem. 277 (2002), 34036–34041.
35. [35] Hendrikx, T., Jeurissen, M.L., Bieghs, V., Walenbergh, S.M., van Gorp, P.J., Verheyen, F., Houben, T., Guichot, Y.D., Gijbels, M.J., Leitersdorf, E., Hofker, M.H., Lutjohann, D., Shiri-Sverdlov, R., Hematopoietic overexpression of Cyp27a1 reduces hepatic inflammation independently of 27-hydroxycholesterol levels in Ldlr(−/−) mice. J. Hepatol. 62 (2015), 430–436.
36. [36] Clayton, P.T., Verrips, A., Sistermans, E., Mann, A., Mieli-Vergani, G., Wevers, R., Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J. Inherit. Metab. Dis. 25 (2002), 501–513.
37. [37] Mignarri, A., Magni, A., Del, P.M., Gallus, G.N., Bjorkhem, I., Federico, A., Dotti, M.T., Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis. J. Inherit. Metab. Dis. 39 (2016), 75–83.
38. [38] Li-Hawkins, J., Lund, E.G., Bronson, A.D., Russell, D.W., Expression cloning of an oxysterol 7alpha-hydroxylase selective for 24-hydroxycholesterol. J. Biol. Chem. 275 (2000), 16543–16549.
39. [39] Lund, E.G., Guileyardo, J.M., Russell, D.W., cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 7238–7243.
40. [40] Goyal, S., Xiao, Y., Porter, N.A., Xu, L., Guengerich, F.P., Oxidation of 7-dehydrocholesterol and desmosterol by human cytochrome P450 46A1. J. Lipid Res. 55 (2014), 1933–1943.
41. [41] Boussicault, L., Alves, S., Lamaziere, A., Planques, A., Heck, N., Moumne, L., Despres, G., Bolte, S., Hu, A., Pages, C., Galvan, L., Piguet, F., Aubourg, P., Cartier, N., Caboche, J., Betuing, S., CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease. Brain 139 (2016), 953–970.
42. [42] Djelti, F., Braudeau, J., Hudry, E., Dhenain, M., Varin, J., Bieche, I., Marquer, C., Chali, F., Ayciriex, S., Auzeil, N., Alves, S., Langui, D., Potier, M.C., Laprevote, O., Vidaud, M., Duyckaerts, C., Miles, R., Aubourg, P., Cartier, N., CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain 138 (2015), 2383–2398.
43. [43] Lund, E.G., Xie, C., Kotti, T., Turley, S.D., Dietschy, J.M., Russell, D.W., Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278 (2003), 22980–22988.
44. [44] Maioli, S., Bavner, A., Ali, Z., Heverin, M., Ismail, M.A., Puerta, E., Olin, M., Saeed, A., Shafaati, M., Parini, P., Cedazo-Minguez, A., Bjorkhem, I., Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain?. PLoS One, 8, 2013, e68534.
45. [45] Laden, B.P., Tang, Y., Porter, T.D., Cloning, heterologous expression, and enzymological characterization of human squalene monooxygenase. Arch. Biochem. Biophys. 374 (2000), 381–388.
46. [46] Schwarz, M., Wright, A.C., Davis, D.L., Nazer, H., Bjorkhem, I., Russell, D.W., The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. J. Clin. Invest. 106 (2000), 1175–1184.
47. [47] Shea, H.C., Head, D.D., Setchell, K.D., Russell, D.W., Analysis of HSD3B7 knockout mice reveals that a 3alpha-hydroxyl stereochemistry is required for bile acid function. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 11526–11533.
48. [48] Cheng, J.B., Jacquemin, E., Gerhardt, M., Nazer, H., Cresteil, D., Heubi, J.E., Setchell, K.D., Russell, D.W., Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J. Clin. Endocrinol. Metab. 88 (2003), 1833–1841.
49. [49] Schweizer, R.A., Zurcher, M., Balazs, Z., Dick, B., Odermatt, A., Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, and hamster enzyme. J. Biol. Chem. 279 (2004), 18415–18424.
50. [50] Mitic, T., Shave, S., Semjonous, N., McNae, I., Cobice, D.F., Lavery, G.G., Webster, S.P., Hadoke, P.W., Walker, B.R., Andrew, R., 11beta-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo. Biochem. Pharmacol. 86 (2013), 146–153.
51. [51] Garcia, R.A., Search, D.J., Lupisella, J.A., Ostrowski, J., Guan, B., Chen, J., Yang, W.P., Truong, A., He, A., Zhang, R., Yan, M., Hellings, S.E., Gargalovic, P.S., Ryan, C.S., Watson, L.M., Langish, R.A., Shipkova, P.A., Carson, N.L., Taylor, J.R., Yang, R., Psaltis, G.C., Harrity, T.W., Robl, J.A., Gordon, D.A., 11beta-Hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE(−)/(−) mice. PLoS One, 8, 2013, e53192.
52. [52] Tiganescu, A., Tahrani, A.A., Morgan, S.A., Otranto, M., Desmouliere, A., Abrahams, L., Hassan-Smith, Z., Walker, E.A., Rabbitt, E.H., Cooper, M.S., Amrein, K., Lavery, G.G., Stewart, P.M., 11beta-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J. Clin. Invest. 123 (2013), 3051–3060.
53. [53] Yau, J.L., Noble, J., Kenyon, C.J., Ludwig, M., Seckl, J.R., Diurnal and stress-induced intra-hippocampal corticosterone rise attenuated in 11beta-HSD1-deficient mice: a microdialysis study in young and aged mice. Eur. J. Neurosci. 41 (2015), 787–792.
54. [54] Draper, N., Walker, E.A., Bujalska, I.J., Tomlinson, J.W., Chalder, S.M., Arlt, W., Lavery, G.G., Bedendo, O., Ray, D.W., Laing, I., Malunowicz, E., White, P.C., Hewison, M., Mason, P.J., Connell, J.M., Shackleton, C.H., Stewart, P.M., Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat. Genet. 34 (2003), 434–439.
55. [55] Lund, E.G., Kerr, T.A., Sakai, J., Li, W.P., Russell, D.W., cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. J. Biol. Chem. 273 (1998), 34316–34327.
56. [56] Bauman, D.R., Bitmansour, A.D., McDonald, J.G., Thompson, B.M., Liang, G., Russell, D.W., 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 16764–16769.
57. [57] de Medina, P., Paillasse, M.R., Segala, G., Poirot, M., Silvente-Poirot, S., Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 13520–13525.
58. [58] Wang, Z., Yang, X., Chen, L., Zhi, X., Lu, H., Ning, Y., Yeong, J., Chen, S., Yin, L., Wang, X., Li, X., Upregulation of hydroxysteroid sulfotransferase 2B1b promotes hepatic oval cell proliferation by modulating oxysterol-induced LXR activation in a mouse model of liver injury. Arch. Toxicol., 2016.
59. [59] Nelson, D.R., Zeldin, D.C., Hoffman, S.M., Maltais, L.J., Wain, H.M., Nebert, D.W., Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14 (2004), 1–18.
60. [60] Mitton, J.R., Scholan, N.A., Boyd, G.S., The oxidation of cholesterol in rat liver sub-cellular particles. The cholesterol-7-alpha-hydroxylase enzyme system. Eur. J. Biochem. 20 (1971), 569–579.
61. [61] Russell, D.W., The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72 (2003), 137–174.
62. [62] Yoshida, T., Honda, A., Tanaka, N., Matsuzaki, Y., Shoda, J., He, B., Osuga, T., Miyazaki, H., Determination of 7 alpha-hydroxy-4-cholesten-3-one level in plasma using isotope-dilution mass spectrometry and monitoring its circadian rhythm in human as an index of bile acid biosynthesis. J. Chromatogr. B Biomed. Appl. 655 (1994), 179–187.
63. [63] Axelson, M., Bjorkhem, I., Reihner, E., Einarsson, K., The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett. 284 (1991), 216–218.
64. [64] Guillemot-Legris, O., Mutemberezi, V., Cani, P.D., Muccioli, G.G., Obesity is associated with changes in oxysterol metabolism and levels in mice liver, hypothalamus, adipose tissue and plasma. Sci. Rep., 6, 2016, 19694.
65. [65] Galman, C., Arvidsson, I., Angelin, B., Rudling, M., Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J. Lipid Res. 44 (2003), 859–866.
66. [66] Eusufzai, S., Axelson, M., Angelin, B., Einarsson, K., Serum 7 alpha-hydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test. Gut 34 (1993), 698–701.
67. [67] Johnston, I.M., Nolan, J.D., Pattni, S.S., Appleby, R.N., Zhang, J.H., Kennie, S.L., Madhan, G.K., Jameie-Oskooei, S., Pathmasrirengam, S., Lin, J., Hong, A., Dixon, P.H., Williamson, C., Walters, J.R., Characterizing factors associated with differences in FGF19 blood levels and synthesis in patients with primary bile acid diarrhea. Am. J. Gastroenterol., 2016.
68. [68] Borup, C., Syversen, C., Bouchelouche, P., Damgaard, M., Graff, J., Rumessen, J.J., Munck, L.K., Diagnosis of bile acid diarrhoea by fasting and postprandial measurements of fibroblast growth factor 19. Eur. J. Gastroenterol. Hepatol. 27 (2015), 1399–1402.
69. [69] Bjorkhem, I., Diczfalusy, U., Lovgren-Sandblom, A., Starck, L., Jonsson, M., Tallman, K., Schirmer, H., Ousager, L.B., Crick, P.J., Wang, Y., Griffiths, W.J., Guengerich, F.P., On the formation of 7-ketocholesterol from 7-dehydrocholesterol in patients with CTX and SLO. J. Lipid Res. 55 (2014), 1165–1172.
70. [70] Shinkyo, R., Xu, L., Tallman, K.A., Cheng, Q., Porter, N.A., Guengerich, F.P., Conversion of 7-dehydrocholesterol to 7-ketocholesterol is catalyzed by human cytochrome P450 7A1 and occurs by direct oxidation without an epoxide intermediate. J. Biol. Chem. 286 (2011), 33021–33028.
71. [71] Theofilopoulos, S., Griffiths, W.J., Crick, P.J., Yang, S., Meljon, A., Ogundare, M., Kitambi, S.S., Lockhart, A., Tuschl, K., Clayton, P.T., Morris, A.A., Martinez, A., Reddy, M.A., Martinuzzi, A., Bassi, M.T., Honda, A., Mizuochi, T., Kimura, A., Nittono, H., De, M.G., Carbone, R., Criscuolo, C., Yau, J.L., Seckl, J.R., Schule, R., Schols, L., Sailer, A.W., Kuhle, J., Fraidakis, M.J., Gustafsson, J.A., Steffensen, K.R., Bjorkhem, I., Ernfors, P., Sjovall, J., Arenas, E., Wang, Y., Cholestenoic acids regulate motor neuron survival via liver X receptors. J. Clin. Invest. 124 (2014), 4829–4842.
72. [72] Bodin, K., Andersson, U., Rystedt, E., Ellis, E., Norlin, M., Pikuleva, I., Eggertsen, G., Bjorkhem, I., Diczfalusy, U., Metabolism of 4 beta-hydroxycholesterol in humans. J. Biol. Chem. 277 (2002), 31534–31540.
73. [73] Diczfalusy, U., Kanebratt, K.P., Bredberg, E., Andersson, T.B., Bottiger, Y., Bertilsson, L., 4beta-Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br. J. Clin. Pharmacol. 67 (2009), 38–43.
74. [74] Diczfalusy, U., Miura, J., Roh, H.K., Mirghani, R.A., Sayi, J., Larsson, H., Bodin, K.G., Allqvist, A., Jande, M., Kim, J.W., Aklillu, E., Gustafsson, L.L., Bertilsson, L., 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet. Genomics 18 (2008), 201–208.
75. [75] Kasichayanula, S., Boulton, D.W., Luo, W.L., Rodrigues, A.D., Yang, Z., Goodenough, A., Lee, M., Jemal, M., LaCreta, F., Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. Br. J. Clin. Pharmacol. 78 (2014), 1122–1134.
76. [76] de Graan, A.J., Sparreboom, A., de Bruijn, P., de Jonge, E., van der Holt, B., Wiemer, E.A., Verweij, J., Mathijssen, R.H., van Schaik, R.H., 4beta-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. Br. J. Clin. Pharmacol. 80 (2015), 560–568.
77. [77] Suzuki, Y., Fujioka, T., Sato, F., Matsumoto, K., Muraya, N., Tanaka, R., Sato, Y., Ohno, K., Mimata, H., Kishino, S., Itoh, H., CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease. Br. J. Clin. Pharmacol. 80 (2015), 1421–1428.
78. [78] Xue, Y.J., Hoffmann, M., Tong, Z., Wu, X.I., Vallejo, M., Melo, B., Ye, Y., Thomas, M., Liu, Y., Weiss, D., Surapaneni, S., Use of 4beta-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. Bioanalysis 8 (2016), 215–228.
79. [79] Ramirez, D.M., Andersson, S., Russell, D.W., Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J. Comp. Neurol. 507 (2008), 1676–1693.
80. [80] Zhang, J., Liu, Q., Cholesterol metabolism and homeostasis in the brain. Protein Cell 6 (2015), 254–264.
81. [81] Ogundare, M., Theofilopoulos, S., Lockhart, A., Hall, L.J., Arenas, E., Sjovall, J., Brenton, A.G., Wang, Y., Griffiths, W.J., Cerebrospinal fluid steroidomics: are bioactive bile acids present in brain?. J. Biol. Chem. 285 (2010), 4666–4679.
82. [82] Ikegami, T., Honda, A., Miyazaki, T., Kohjima, M., Nakamuta, M., Matsuzaki, Y., Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. Biochem. Biophys. Res. Commun. 446 (2014), 736–740.
83. [83] Stiles, A.R., Kozlitina, J., Thompson, B.M., McDonald, J.G., King, K.S., Russell, D.W., Genetic, anatomic, and clinical determinants of human serum sterol and vitamin D levels. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E4006–E4014.
84. [84] Wang, Y., Karu, K., Meljon, A., Turton, J., Yau, J.L., Seckl, J.R., Wang, Y., Griffiths, W.J., 24S,25-Epoxycholesterol in mouse and rat brain. Biochem. Biophys. Res. Commun. 449 (2014), 229–234.
85. [85] Sharpe, L.J., Brown, A.J., Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J. Biol. Chem. 288 (2013), 18707–18715.
86. [86] Pagotto, M.A., Roldan, M.L., Pagotto, R.M., Lugano, M.C., Pisani, G.B., Rogic, G., Molinas, S.M., Trumper, L., Pignataro, O.P., Monasterolo, L.A., Localization and functional activity of cytochrome P450 side chain cleavage enzyme (CYP11A1) in the adult rat kidney. Mol. Cell. Endocrinol. 332 (2011), 253–260.
87. [87] Li, J., Daly, E., Campioli, E., Wabitsch, M., Papadopoulos, V., De novo synthesis of steroids and oxysterols in adipocytes. J. Biol. Chem. 289 (2014), 747–764.
88. [88] Heo, G.Y., Liao, W.L., Turko, I.V., Pikuleva, I.A., Features of the retinal environment which affect the activities and product profile of cholesterol-metabolizing cytochromes P450 CYP27A1 and CYP11A1. Arch. Biochem. Biophys. 518 (2012), 119–126.
89. [89] Mitic, T., Andrew, R., Walker, B.R., Hadoke, P.W., 11beta-Hydroxysteroid dehydrogenase type 1 contributes to the regulation of 7-oxysterol levels in the arterial wall through the inter-conversion of 7-ketocholesterol and 7beta-hydroxycholesterol. Biochimie 95 (2013), 548–555.
90. [90] Tortorella, C., Aragona, F., Nussdorfer, G.G., In vivo evidence that human adrenal glands possess 11 beta-hydroxysteroid dehydrogenase activity. Life Sci. 65 (1999), 2823–2827.
91. [91] Honda, A., Miyazaki, T., Ikegami, T., Iwamoto, J., Maeda, T., Hirayama, T., Saito, Y., Teramoto, T., Matsuzaki, Y., Cholesterol 25-hydroxylation activity of CYP3A. J. Lipid Res. 52 (2011), 1509–1516.
92. [92] Diczfalusy, U., Bjorkhem, I., Still another activity by the highly promiscuous enzyme CYP3A4: 25-hydroxylation of cholesterol. J. Lipid Res. 52 (2011), 1447–1449.
93. [93] Liu, S.Y., Aliyari, R., Chikere, K., Li, G., Marsden, M.D., Smith, J.K., Pernet, O., Guo, H., Nusbaum, R., Zack, J.A., Freiberg, A.N., Su, L., Lee, B., Cheng, G., Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 38 (2013), 92–105.
94. [94] Blanc, M., Hsieh, W.Y., Robertson, K.A., Kropp, K.A., Forster, T., Shui, G., Lacaze, P., Watterson, S., Griffiths, S.J., Spann, N.J., Meljon, A., Talbot, S., Krishnan, K., Covey, D.F., Wenk, M.R., Craigon, M., Ruzsics, Z., Haas, J., Angulo, A., Griffiths, W.J., Glass, C.K., Wang, Y., Ghazal, P., The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity 38 (2013), 106–118.
95. [95] Newman, J.W., Morisseau, C., Hammock, B.D., Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 44 (2005), 1–51.
96. [96] Boenzi, S., Deodato, F., Taurisano, R., Goffredo, B.M., Rizzo, C., Dionisi-Vici, C., Evaluation of plasma cholestane-3beta,5alpha,6beta-triol and 7-ketocholesterol in inherited disorders related to cholesterol metabolism. J. Lipid Res. 57 (2016), 361–367.
97. [97] Pajares, S., Arias, A., Garcia-Villoria, J., Macias-Vidal, J., Ros, E., de las Heras, J., Giros, M., Coll, M.J., Ribes, A., Cholestane-3beta,5alpha,6beta-triol: high levels in Niemann-Pick type C, cerebrotendinous xanthomatosis, and lysosomal acid lipase deficiency. J. Lipid Res. 56 (2015), 1926–1935.
98. [98] Romanello, M., Zampieri, S., Bortolotti, N., Deroma, L., Sechi, A., Fiumara, A., Parini, R., Borroni, B., Brancati, F., Bruni, A., Russo, C.V., Bordugo, A., Bembi, B., Dardis, A., Comprehensive evaluation of plasma 7-ketocholesterol and cholestan-3beta,5alpha,6beta-triol in an Italian cohort of patients affected by Niemann-Pick disease due to NPC1 and SMPD1 mutations. Clin. Chim. Acta 455 (2016), 39–45.
99. [99] Silvente-Poirot, S., Poirot, M., Cholesterol epoxide hydrolase and cancer. Curr. Opin. Pharmacol. 12 (2012), 696–703.
100. [100] Brown, A.J., Mander, E.L., Gelissen, I.C., Kritharides, L., Dean, R.T., Jessup, W., Cholesterol and oxysterol metabolism and subcellular distribution in macrophage foam cells. Accumulation of oxidized esters in lysosomes. J. Lipid Res. 41 (2000), 226–237.
101. [101] Russell, D.W., Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta 1529 (2000), 126–135.
102. [102] Brown, A.J., Jessup, W., Oxysterols: sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol. Asp. Med. 30 (2009), 111–122.
103. [103] Javitt, N.B., Lee, Y.C., Shimizu, C., Fuda, H., Strott, C.A., Cholesterol and hydroxycholesterol sulfotransferases: identification, distinction from dehydroepiandrosterone sulfotransferase, and differential tissue expression. Endocrinology 142 (2001), 2978–2984.
104. [104] Fuda, H., Javitt, N.B., Mitamura, K., Ikegawa, S., Strott, C.A., Oxysterols are substrates for cholesterol sulfotransferase. J. Lipid Res. 48 (2007), 1343–1352.
105. [105] Salman, E.D., Faye-Petersen, O., Falany, C.N., Hydroxysteroid sulfotransferase 2B1b expression and localization in normal human brain. Horm. Mol. Biol. Clin. Invest. 8 (2011), 445–454.
106. [106] Xu, L., Kim, J.K., Bai, Q., Zhang, X., Kakiyama, G., Min, H.K., Sanyal, A.J., Pandak, W.M., Ren, S., 5-Cholesten-3beta,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol. Pharmacol. 83 (2013), 648–658.
107. [107] Ren, S., Li, X., Rodriguez-Agudo, D., Gil, G., Hylemon, P., Pandak, W.M., Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes. Biochem. Biophys. Res. Commun. 360 (2007), 802–808.
108. [108] Jakobsson, T., Treuter, E., Gustafsson, J.A., Steffensen, K.R., Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol. Sci. 33 (2012), 394–404.
109. [109] Hong, C., Tontonoz, P., Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat. Rev. Drug Discov. 13 (2014), 433–444.
110. [110] Lee, S.D., Tontonoz, P., Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 242 (2015), 29–36.
111. [111] Meffre, D., Shackleford, G., Hichor, M., Gorgievski, V., Tzavara, E.T., Trousson, A., Ghoumari, A.M., Deboux, C., Nait, O.B., Liere, P., Schumacher, M., Baulieu, E.E., Charbonnier, F., Grenier, J., Massaad, C., Liver X receptors alpha and beta promote myelination and remyelination in the cerebellum. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 7587–7592.
112. [112] Berrodin, T.J., Shen, Q., Quinet, E.M., Yudt, M.R., Freedman, L.P., Nagpal, S., Identification of 5alpha, 6alpha-epoxycholesterol as a novel modulator of liver X receptor activity. Mol. Pharmacol. 78 (2010), 1046–1058.
113. [113] Wang, Y., Kumar, N., Crumbley, C., Griffin, P.R., Burris, T.P., A second class of nuclear receptors for oxysterols: regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol). Biochim. Biophys. Acta 2010 (1801), 917–923.
114. [114] Wang, Y., Kumar, N., Solt, L.A., Richardson, T.I., Helvering, L.M., Crumbley, C., Garcia-Ordonez, R.D., Stayrook, K.R., Zhang, X., Novick, S., Chalmers, M.J., Griffin, P.R., Burris, T.P., Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands. J. Biol. Chem. 285 (2010), 5013–5025.
115. [115] Kojetin, D.J., Burris, T.P., REV-ERB and ROR nuclear receptors as drug targets. Nat. Rev. Drug Discov. 13 (2014), 197–216.
116. [116] Soroosh, P., Wu, J., Xue, X., Song, J., Sutton, S.W., Sablad, M., Yu, J., Nelen, M.I., Liu, X., Castro, G., Luna, R., Crawford, S., Banie, H., Dandridge, R.A., Deng, X., Bittner, A., Kuei, C., Tootoonchi, M., Rozenkrants, N., Herman, K., Gao, J., Yang, X.V., Sachen, K., Ngo, K., Fung-Leung, W.P., Nguyen, S., de Leon-Tabaldo, A., Blevitt, J., Zhang, Y., Cummings, M.D., Rao, T., Mani, N.S., Liu, C., McKinnon, M., Milla, M.E., Fourie, A.M., Sun, S., Oxysterols are agonist ligands of RORgammat and drive Th17 cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 12163–12168.
117. [117] Hu, X., Wang, Y., Hao, L.Y., Liu, X., Lesch, C.A., Sanchez, B.M., Wendling, J.M., Morgan, R.W., Aicher, T.D., Carter, L.L., Toogood, P.L., Glick, G.D., Sterol metabolism controls T(H)17 differentiation by generating endogenous RORgamma agonists. Nat. Chem. Biol. 11 (2015), 141–147.
118. [118] Lappano, R., Recchia, A.G., De Francesco, E.M., Angelone, T., Cerra, M.C., Picard, D., Maggiolini, M., The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes. PLoS One, 6, 2011, e16631.
119. [119] DuSell, C.D., Umetani, M., Shaul, P.W., Mangelsdorf, D.J., McDonnell, D.P., 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol. Endocrinol. 22 (2008), 65–77.
120. [120] Nelson, E.R., Wardell, S.E., McDonnell, D.P., The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis. Bone 53 (2013), 42–50.
121. [121] Nury, T., Samadi, M., Varin, A., Lopez, T., Zarrouk, A., Boumhras, M., Riedinger, J.M., Masson, D., Vejux, A., Lizard, G., Biological activities of the LXRalpha and beta agonist, 4beta-hydroxycholesterol, and of its isomer, 4alpha-hydroxycholesterol, on oligodendrocytes: effects on cell growth and viability, oxidative and inflammatory status. Biochimie 95 (2013), 518–530.
122. [122] Song, C., Hiipakka, R.A., Liao, S., Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids 66 (2001), 473–479.
123. [123] Janowski, B.A., Grogan, M.J., Jones, S.A., Wisely, G.B., Kliewer, S.A., Corey, E.J., Mangelsdorf, D.J., Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 266–271.
124. [124] Ma, Y., Xu, L., Rodriguez-Agudo, D., Li, X., Heuman, D.M., Hylemon, P.B., Pandak, W.M., Ren, S., 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am. J. Physiol. Endocrinol. Metab. 295 (2008), E1369–E1379.
125. [125] Fu, X., Menke, J.G., Chen, Y., Zhou, G., MacNaul, K.L., Wright, S.D., Sparrow, C.P., Lund, E.G., 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276 (2001), 38378–38387.
126. [126] Bitsch, F., Aichholz, R., Kallen, J., Geisse, S., Fournier, B., Schlaeppi, J.M., Identification of natural ligands of retinoic acid receptor-related orphan receptor alpha ligand-binding domain expressed in Sf9 cells—a mass spectrometry approach. Anal. Biochem. 323 (2003), 139–149.
127. [127] Jin, L., Martynowski, D., Zheng, S., Wada, T., Xie, W., Li, Y., Structural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORgamma. Mol. Endocrinol. 24 (2010), 923–929.
128. [128] Kumar, N., Solt, L.A., Conkright, J.J., Wang, Y., Istrate, M.A., Busby, S.A., Garcia-Ordonez, R.D., Burris, T.P., Griffin, P.R., The benzenesulfonamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethy l]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Mol. Pharmacol. 77 (2010), 228–236.
129. [129] Nedelcu, D., Liu, J., Xu, Y., Jao, C., Salic, A., Oxysterol binding to the extracellular domain of Smoothened in Hedgehog signaling. Nat. Chem. Biol. 9 (2013), 557–564.
130. [130] Nachtergaele, S., Mydock, L.K., Krishnan, K., Rammohan, J., Schlesinger, P.H., Covey, D.F., Rohatgi, R., Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat. Chem. Biol. 8 (2012), 211–220.
131. [131] Liu, C., Yang, X.V., Wu, J., Kuei, C., Mani, N.S., Zhang, L., Yu, J., Sutton, S.W., Qin, N., Banie, H., Karlsson, L., Sun, S., Lovenberg, T.W., Oxysterols direct B-cell migration through EBI2. Nature 475 (2011), 519–523.
132. [132] Hannedouche, S., Zhang, J., Yi, T., Shen, W., Nguyen, D., Pereira, J.P., Guerini, D., Baumgarten, B.U., Roggo, S., Wen, B., Knochenmuss, R., Noel, S., Gessier, F., Kelly, L.M., Vanek, M., Laurent, S., Preuss, I., Miault, C., Christen, I., Karuna, R., Li, W., Koo, D.I., Suply, T., Schmedt, C., Peters, E.C., Falchetto, R., Katopodis, A., Spanka, C., Roy, M.O., Detheux, M., Chen, Y.A., Schultz, P.G., Cho, C.Y., Seuwen, K., Cyster, J.G., Sailer, A.W., Oxysterols direct immune cell migration via EBI2. Nature 475 (2011), 524–527.
133. [133] Sensi, C., Daniele, S., Parravicini, C., Zappelli, E., Russo, V., Trincavelli, M.L., Martini, C., Abbracchio, M.P., Eberini, I., Oxysterols act as promiscuous ligands of class-A GPCRs: in silico molecular modeling and in vitro validation. Cell. Signal. 26 (2014), 2614–2620.
134. [134] Raccosta, L., Fontana, R., Maggioni, D., Lanterna, C., Villablanca, E.J., Paniccia, A., Musumeci, A., Chiricozzi, E., Trincavelli, M.L., Daniele, S., Martini, C., Gustafsson, J.A., Doglioni, C., Feo, S.G., Leiva, A., Ciampa, M.G., Mauri, L., Sensi, C., Prinetti, A., Eberini, I., Mora, J.R., Bordignon, C., Steffensen, K.R., Sonnino, S., Sozzani, S., Traversari, C., Russo, V., The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J. Exp. Med. 210 (2013), 1711–1728.
135. [135] Benned-Jensen, T., Norn, C., Laurent, S., Madsen, C.M., Larsen, H.M., Arfelt, K.N., Wolf, R.M., Frimurer, T., Sailer, A.W., Rosenkilde, M.M., Molecular characterization of oxysterol binding to the Epstein-Barr virus-induced gene 2 (GPR183). J. Biol. Chem. 287 (2012), 35470–35483.
136. [136] Chalmin, F., Rochemont, V., Lippens, C., Clottu, A., Sailer, A.W., Merkler, D., Hugues, S., Pot, C., Oxysterols regulate encephalitogenic CD4(+) T cell trafficking during central nervous system autoimmunity. J. Autoimmun. 56 (2015), 45–55.
137. [137] Sun, S., Liu, C., 7alpha, 25-Dihydroxycholesterol-mediated activation of EBI2 in immune regulation and diseases. Front. Pharmacol., 6, 2015, 60.
138. [138] Ciana, P., Fumagalli, M., Trincavelli, M.L., Verderio, C., Rosa, P., Lecca, D., Ferrario, S., Parravicini, C., Capra, V., Gelosa, P., Guerrini, U., Belcredito, S., Cimino, M., Sironi, L., Tremoli, E., Rovati, G.E., Martini, C., Abbracchio, M.P., The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 25 (2006), 4615–4627.
139. [139] Myers, B.R., Sever, N., Chong, Y.C., Kim, J., Belani, J.D., Rychnovsky, S., Bazan, J.F., Beachy, P.A., Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response. Dev. Cell 26 (2013), 346–357.
140. [140] Nachtergaele, S., Whalen, D.M., Mydock, L.K., Zhao, Z., Malinauskas, T., Krishnan, K., Ingham, P.W., Covey, D.F., Siebold, C., Rohatgi, R., Structure and function of the Smoothened extracellular domain in vertebrate Hedgehog signaling. Elife, 2, 2013, e01340.
141. [141] Paul, S.M., Doherty, J.J., Robichaud, A.J., Belfort, G.M., Chow, B.Y., Hammond, R.S., Crawford, D.C., Linsenbardt, A.J., Shu, H.J., Izumi, Y., Mennerick, S.J., Zorumski, C.F., The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J. Neurosci. 33 (2013), 17290–17300.
142. [142] Linsenbardt, A.J., Taylor, A., Emnett, C.M., Doherty, J.J., Krishnan, K., Covey, D.F., Paul, S.M., Zorumski, C.F., Mennerick, S., Different oxysterols have opposing actions at N-methyl-D-aspartate receptors. Neuropharmacology 85 (2014), 232–242.
143. [143] Radhakrishnan, A., Ikeda, Y., Kwon, H.J., Brown, M.S., Goldstein, J.L., Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 6511–6518.
144. [144] Hynynen, R., Suchanek, M., Spandl, J., Back, N., Thiele, C., Olkkonen, V.M., OSBP-related protein 2 is a sterol receptor on lipid droplets that regulates the metabolism of neutral lipids. J. Lipid Res. 50 (2009), 1305–1315.
145. [145] Bowden, K., Ridgway, N.D., OSBP negatively regulates ABCA1 protein stability. J. Biol. Chem. 283 (2008), 18210–18217.
146. [146] Ohgane, K., Karaki, F., Noguchi-Yachide, T., Dodo, K., Hashimoto, Y., Structure-activity relationships of oxysterol-derived pharmacological chaperones for Niemann-Pick type C1 protein. Bioorg. Med. Chem. Lett. 24 (2014), 3480–3485.
147. [147] Infante, R.E., Abi-Mosleh, L., Radhakrishnan, A., Dale, J.D., Brown, M.S., Goldstein, J.L., Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. J. Biol. Chem. 283 (2008), 1052–1063.
148. [148] Soccio, R.E., Adams, R.M., Maxwell, K.N., Breslow, J.L., Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins. Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress. J. Biol. Chem. 280 (2005), 19410–19418.
149. [149] Olkkonen, V.M., Li, S., Oxysterol-binding proteins: sterol and phosphoinositide sensors coordinating transport, signaling and metabolism. Prog. Lipid Res. 52 (2013), 529–538.
150. [150] Letourneau, D., Lefebvre, A., Lavigne, P., LeHoux, J.G., The binding site specificity of STARD4 subfamily: breaking the cholesterol paradigm. Mol. Cell. Endocrinol. 408 (2015), 53–61.
151. [151] Higgins, M.E., Davies, J.P., Chen, F.W., Ioannou, Y.A., Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network. Mol. Genet. Metab. 68 (1999), 1–13.
152. [152] Ioannou, Y.A., The structure and function of the Niemann-Pick C1 protein. Mol. Genet. Metab. 71 (2000), 175–181.
153. [153] Liou, H.L., Dixit, S.S., Xu, S., Tint, G.S., Stock, A.M., Lobel, P., NPC2, the protein deficient in Niemann-Pick C2 disease, consists of multiple glycoforms that bind a variety of sterols. J. Biol. Chem. 281 (2006), 36710–36723.
154. [154] Frolov, A., Zielinski, S.E., Crowley, J.R., Dudley-Rucker, N., Schaffer, J.E., Ory, D.S., NPC1 and NPC2 regulate cellular cholesterol homeostasis through generation of low density lipoprotein cholesterol-derived oxysterols. J. Biol. Chem. 278 (2003), 25517–25525.
155. [155] Tong, J., Manik, M.K., Yang, H., Im, Y.J., Structural insights into nonvesicular lipid transport by the oxysterol binding protein homologue family. Biochim. Biophys. Acta, 2016.
156. [156] Anniss, A.M., Apostolopoulos, J., Dworkin, S., Purton, L.E., Sparrow, R.L., An oxysterol-binding protein family identified in the mouse. DNA Cell Biol. 21 (2002), 571–580.
157. [157] Weber-Boyvat, M., Zhong, W., Yan, D., Olkkonen, V.M., Oxysterol-binding proteins: functions in cell regulation beyond lipid metabolism. Biochem. Pharmacol. 86 (2013), 89–95.
158. [158] Drin, G., von Filseck, J.M., Copic, A., New molecular mechanisms of inter-organelle lipid transport. Biochem. Soc. Trans. 44 (2016), 486–492.
159. [159] Wang, P.Y., Weng, J., Anderson, R.G., OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation. Science 307 (2005), 1472–1476.
160. [160] Yan, D., Mayranpaa, M.I., Wong, J., Perttila, J., Lehto, M., Jauhiainen, M., Kovanen, P.T., Ehnholm, C., Brown, A.J., Olkkonen, V.M., OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages. J. Biol. Chem. 283 (2008), 332–340.
161. [161] Calderon-Dominguez, M., Gil, G., Medina, M.A., Pandak, W.M., Rodriguez-Agudo, D., The StarD4 subfamily of steroidogenic acute regulatory-related lipid transfer (START) domain proteins: new players in cholesterol metabolism. Int. J. Biochem. Cell Biol. 49 (2014), 64–68.
162. [162] Rodriguez-Agudo, D., Ren, S., Hylemon, P.B., Redford, K., Natarajan, R., Del, C.A., Gil, G., Pandak, W.M., Human StarD5, a cytosolic StAR-related lipid binding protein. J. Lipid Res. 46 (2005), 1615–1623.
163. [163] Ning, Y., Bai, Q., Lu, H., Li, X., Pandak, W.M., Zhao, F., Chen, S., Ren, S., Yin, L., Overexpression of mitochondrial cholesterol delivery protein, StAR, decreases intracellular lipids and inflammatory factors secretion in macrophages. Atherosclerosis 204 (2009), 114–120.
164. [164] Taylor, J.M., Borthwick, F., Bartholomew, C., Graham, A., Overexpression of steroidogenic acute regulatory protein increases macrophage cholesterol efflux to apolipoprotein AI. Cardiovasc. Res. 86 (2010), 526–534.
165. [165] Erickson, S.K., Lear, S.R., Deane, S., Dubrac, S., Huling, S.L., Nguyen, L., Bollineni, J.S., Shefer, S., Hyogo, H., Cohen, D.E., Shneider, B., Sehayek, E., Ananthanarayanan, M., Balasubramaniyan, N., Suchy, F.J., Batta, A.K., Salen, G., Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44 (2003), 1001–1009.
166. [166] Tiemann, M., Han, Z., Soccio, R., Bollineni, J., Shefer, S., Sehayek, E., Breslow, J.L., Cholesterol feeding of mice expressing cholesterol 7alpha-hydroxylase increases bile acid pool size despite decreased enzyme activity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 1846–1851.
167. [167] Heverin, M., Ali, Z., Olin, M., Tillander, V., Joibari, M.M., Makoveichuk, E., Leitersdorf, E., Warner, M., Olivercrona, G., Gustafsson, J.A., Bjorkhem, I., On the regulatory importance of 27-hydroxycholesterol in mouse liver. J. Steroid Biochem. Mol. Biol., 2016.
168. [168] Stiles, A.R., McDonald, J.G., Bauman, D.R., Russell, D.W., CYP7B1: one cytochrome P450, two human genetic diseases, and multiple physiological functions. J. Biol. Chem. 284 (2009), 28485–28489.
169. [169] Yi, T., Wang, X., Kelly, L.M., An, J., Xu, Y., Sailer, A.W., Gustafsson, J.A., Russell, D.W., Cyster, J.G., Oxysterol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. Immunity 37 (2012), 535–548.
170. [170] Chen, J.H., Peng, D.Q., Is 25-hydroxycholesterol the interplay of statins and inflammation?. Int. J. Cardiol. 184 (2015), 255–256.
171. [171] Cyster, J.G., Dang, E.V., Reboldi, A., Yi, T., 25-Hydroxycholesterols in innate and adaptive immunity. Nat. Rev. Immunol. 14 (2014), 731–743.
172. [172] Gold, E.S., Diercks, A.H., Podolsky, I., Podyminogin, R.L., Askovich, P.S., Treuting, P.M., Aderem, A., 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 10666–10671.
173. [173] Reboldi, A., Dang, E.V., McDonald, J.G., Liang, G., Russell, D.W., Cyster, J.G., Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science 345 (2014), 679–684.
174. [174] Dubrac, S., Lear, S.R., Ananthanarayanan, M., Balasubramaniyan, N., Bollineni, J., Shefer, S., Hyogo, H., Cohen, D.E., Blanche, P.J., Krauss, R.M., Batta, A.K., Salen, G., Suchy, F.J., Maeda, N., Erickson, S.K., Role of CYP27A in cholesterol and bile acid metabolism. J. Lipid Res. 46 (2005), 76–85.
175. [175] Bieghs, V., Hendrikx, T., van Gorp, P.J., Verheyen, F., Guichot, Y.D., Walenbergh, S.M., Jeurissen, M.L., Gijbels, M., Rensen, S.S., Bast, A., Plat, J., Kalhan, S.C., Koek, G.H., Leitersdorf, E., Hofker, M.H., Lutjohann, D., Shiri-Sverdlov, R., The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. Gastroenterology 144 (2013), 167–178.
176. [176] McDonnell, D.P., Park, S., Goulet, M.T., Jasper, J., Wardell, S.E., Chang, C.Y., Norris, J.D., Guyton, J.R., Nelson, E.R., Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res. 74 (2014), 4976–4982.
177. [177] Nelson, E.R., Wardell, S.E., Jasper, J.S., Park, S., Suchindran, S., Howe, M.K., Carver, N.J., Pillai, R.V., Sullivan, P.M., Sondhi, V., Umetani, M., Geradts, J., McDonnell, D.P., 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342 (2013), 1094–1098.
178. [178] Gamba, P., Testa, G., Gargiulo, S., Staurenghi, E., Poli, G., Leonarduzzi, G., Oxidized cholesterol as the driving force behind the development of Alzheimer's disease. Front. Aging Neurosci., 7, 2015, 119.
179. [179] Meljon, A., Wang, Y., Griffiths, W.J., Oxysterols in the brain of the cholesterol 24-hydroxylase knockout mouse. Biochem. Biophys. Res. Commun. 446 (2014), 768–774.
180. [180] Hudry, E., Van, D.D., Kulik, W., De Deyn, P.P., Stet, F.S., Ahouansou, O., Benraiss, A., Delacourte, A., Bougneres, P., Aubourg, P., Cartier, N., Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther. 18 (2010), 44–53.
181. [181] van Herwaarden, A.E., Wagenaar, E., van der Kruijssen, C.M., van Waterschoot, R.A., Smit, J.W., Song, J.Y., van der Valk, M.A., van Tellingen, O., van der Hoorn, J.W., Rosing, H., Beijnen, J.H., Schinkel, A.H., Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest. 117 (2007), 3583–3592.
182. [182] Guillemot-Legris, O., Mutemberezi, V., Muccioli, G.G., Oxysterols in metabolic syndrome: from bystander molecules to bioactive lipids. Trends Mol. Med. 22 (2016), 594–614.
183. [183] Poli, G., Biasi, F., Leonarduzzi, G., Oxysterols in the pathogenesis of major chronic diseases. Redox Biol. 1 (2013), 125–130.
184. [184] Pataj, Z., Liebisch, G., Schmitz, G., Matysik, S., Quantification of oxysterols in human plasma and red blood cells by liquid chromatography high-resolution tandem mass spectrometry. J. Chromatogr. A 1439 (2016), 82–88.
185. [185] Schott, H.F., Lutjohann, D., Validation of an isotope dilution gas chromatography–mass spectrometry method for combined analysis of oxysterols and oxyphytosterols in serum samples. Steroids 99 (2015), 139–150.
186. [186] Mutemberezi, V., Masquelier, J., Guillemot-Legris, O., Muccioli, G.G., Development and validation of an HPLC-MS method for the simultaneous quantification of key oxysterols, endocannabinoids, and ceramides: variations in metabolic syndrome. Anal. Bioanal. Chem. 408 (2016), 733–745.
187. [187] Griffiths, W.J., Abdel-Khalik, J., Crick, P.J., Yutuc, E., Wang, Y., New methods for analysis of oxysterols and related compounds by LC-MS. J. Steroid Biochem. Mol. Biol., 2015.
188. [188] Oda, H., Yamashita, H., Kosahara, K., Kuroki, S., Nakayama, F., Esterified and total 7 alpha-hydroxycholesterol in human serum as an indicator for hepatic bile acid synthesis. J. Lipid Res. 31 (1990), 2209–2218.
189. [189] Dzeletovic, S., Breuer, O., Lund, E., Diczfalusy, U., Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal. Biochem. 225 (1995), 73–80.
190. [190] Wang, H.L., Wang, Y.Y., Liu, X.G., Kuo, S.H., Liu, N., Song, Q.Y., Wang, M.W., Cholesterol, 24-hydroxycholesterol, and 27-hydroxycholesterol as surrogate biomarkers in cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease: a meta-analysis. J. Alzheimers Dis. 51 (2016), 45–55.
191. [191] Bjorkhem, I., Lovgren-Sandblom, A., Leoni, V., Meaney, S., Brodin, L., Salveson, L., Winge, K., Palhagen, S., Svenningsson, P., Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci. Lett. 555 (2013), 102–105.
192. [192] Iuliano, L., Crick, P.J., Zerbinati, C., Tritapepe, L., Abdel-Khalik, J., Poirot, M., Wang, Y., Griffiths, W.J., Cholesterol metabolites exported from human brain. Steroids 99 (2015), 189–193.
193. [193] Helmschrodt, C., Becker, S., Schroter, J., Hecht, M., Aust, G., Thiery, J., Ceglarek, U., Fast LC-MS/MS analysis of free oxysterols derived from reactive oxygen species in human plasma and carotid plaque. Clin. Chim. Acta 425 (2013), 3–8.
194. [194] Wooten, J.S., Wu, H., Raya, J., Perrard, X.D., Gaubatz, J., Hoogeveen, R.C., The influence of an obesogenic diet on oxysterol metabolism in C57BL/6J mice. Cholesterol, 2014, 2014, 843468.
195. [195] Ahonen, L., Maire, F.B., Savolainen, M., Kopra, J., Vreeken, R.J., Hankemeier, T., Myohanen, T., Kylli, P., Kostiainen, R., Analysis of oxysterols and vitamin D metabolites in mouse brain and cell line samples by ultra-high-performance liquid chromatography-atmospheric pressure photoionization-mass spectrometry. J. Chromatogr. A 1364 (2014), 214–222.
196. [196] DeBarber, A.E., Luo, J., Star-Weinstock, M., Purkayastha, S., Geraghty, M.T., Chiang, J.P., Merkens, L.S., Pappu, A.S., Steiner, R.D., A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns. J. Lipid Res. 55 (2014), 146–154.
197. [197] Kreilaus, F., Spiro, A.S., Hannan, A.J., Garner, B., Jenner, A.M., Brain cholesterol synthesis and metabolism is progressively disturbed in the R6/1 mouse model of Huntington's disease: a targeted GC–MS/MS sterol analysis. J. Huntingtons. Dis. 4 (2015), 305–318.
198. [198] Honda, A., Yamashita, K., Hara, T., Ikegami, T., Miyazaki, T., Shirai, M., Xu, G., Numazawa, M., Matsuzaki, Y., Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J. Lipid Res. 50 (2009), 350–357.
199. [199] Karuna, R., Christen, I., Sailer, A.W., Bitsch, F., Zhang, J., Detection of dihydroxycholesterols in human plasma using HPLC-ESI-MS/MS. Steroids 99 (2015), 131–138.
200. [200] Kovar, J., Lenicek, M., Zimolova, M., Vitek, L., Jirsa, M., Pitha, J., Regulation of diurnal variation of cholesterol 7alpha-hydroxylase (CYP7A1) activity in healthy subjects. Physiol. Res. 59 (2010), 233–238.
201. [201] Galman, C., Angelin, B., Rudling, M., Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 129 (2005), 1445–1453.
202. [202] Andreyev, A.Y., Fahy, E., Guan, Z., Kelly, S., Li, X., McDonald, J.G., Milne, S., Myers, D., Park, H., Ryan, A., Thompson, B.M., Wang, E., Zhao, Y., Brown, H.A., Merrill, A.H., Raetz, C.R., Russell, D.W., Subramaniam, S., Dennis, E.A., Subcellular organelle lipidomics in TLR-4-activated macrophages. J. Lipid Res. 51 (2010), 2785–2797.
203. [203] Yang, Z., Rodrigues, A.D., Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?. J. Clin. Pharmacol. 50 (2010), 1330–1338.
204. [204] Wide, K., Larsson, H., Bertilsson, L., Diczfalusy, U., Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br. J. Clin. Pharmacol. 65 (2008), 708–715.
205. [205] Du, X., Brown, A.J., Yang, H., Novel mechanisms of intracellular cholesterol transport: oxysterol-binding proteins and membrane contact sites. Curr. Opin. Cell Biol. 35 (2015), 37–42.
206. [206] Gill, S., Chow, R., Brown, A.J., Sterol regulators of cholesterol homeostasis and beyond: the oxysterol hypothesis revisited and revised. Prog. Lipid Res. 47 (2008), 391–404.
207. [207] Bjorkhem, I., Do oxysterols control cholesterol homeostasis?. J. Clin. Invest. 110 (2002), 725–730.
208. [208] Gabbi, C., Warner, M., Gustafsson, J.A., Action mechanisms of liver X receptors. Biochem. Biophys. Res. Commun. 446 (2014), 647–650.
209. [209] Spann, N.J., Glass, C.K., Sterols and oxysterols in immune cell function. Nat. Immunol. 14 (2013), 893–900.
210. [210] Nevius, E., Pinho, F., Dhodapkar, M., Jin, H., Nadrah, K., Horowitz, M.C., Kikuta, J., Ishii, M., Pereira, J.P., Oxysterols and EBI2 promote osteoclast precursor migration to bone surfaces and regulate bone mass homeostasis. J. Exp. Med. 212 (2015), 1931–1946.
211. [211] Kwon, I.K., Lee, S.C., Hwang, Y.S., Heo, J.S., Mitochondrial function contributes to oxysterol-induced osteogenic differentiation in mouse embryonic stem cells. Biochim. Biophys. Acta 2015 (1853), 561–572.
212. [212] Theofilopoulos, S., Wang, Y., Kitambi, S.S., Sacchetti, P., Sousa, K.M., Bodin, K., Kirk, J., Salto, C., Gustafsson, M., Toledo, E.M., Karu, K., Gustafsson, J.A., Steffensen, K.R., Ernfors, P., Sjovall, J., Griffiths, W.J., Arenas, E., Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat. Chem. Biol. 9 (2013), 126–133.
213. [213] Yamanaka, K., Urano, Y., Takabe, W., Saito, Y., Noguchi, N., Induction of apoptosis and necroptosis by 24(S)-hydroxycholesterol is dependent on activity of acyl-CoA:cholesterol acyltransferase 1. Cell Death Dis., 5, 2014, e990.
214. [214] Lorbek, G., Lewinska, M., Rozman, D., Cytochrome P450s in the synthesis of cholesterol and bile acids—from mouse models to human diseases. FEBS J. 279 (2012), 1516–1533.
215. [215] Zanger, U.M., Schwab, M., Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138 (2013), 103–141.
216. [216] Suzuki, Y., Itoh, H., Fujioka, T., Sato, F., Kawasaki, K., Sato, Y., Sato, Y., Ohno, K., Mimata, H., Kishino, S., Association of plasma concentration of 4beta-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. Drug Metab. Dispos. 42 (2014), 105–110.